Corona Remedies Ltd

Corona Remedies Legal & Regulatory

Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.

Value

₹4.88 Cr

Corona Remedies Earnings Call Transcript: Key Takeaways

CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.

Call

Guides 15% growth

Corona Remedies Investor Presentation: Key Takeaways

Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.

Corona Remedies Results Update

Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.

Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY

Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.

Key figure

Net profit ₹60.3 Cr · +15.3% YoY

Corona Remedies Business Update

Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.

Corona Remedies Board Meeting Date

Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.